<DOC>
	<DOCNO>NCT00606450</DOCNO>
	<brief_summary>There unmet medical need safe , effective oral therapy moderate-to-severe psoriasis . CC-10004 evaluate control set clinical study . The information obtain study aid design future clinical trial establish safety efficacy CC-10004 .</brief_summary>
	<brief_title>Double-Blind , Randomized , Placebo-controlled Comparison CC-10004 Subjects With Moderate Severe Plaque Type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Must understand voluntarily sign informed consent form Must good health judge investigator Must able adhere study visit schedule protocol requirement Must great equal 6 month history moderatetosevere plaquetype psoriasis Must Psoriasis Area Severity Index ( PASI ) score great equal 10 Body Surface Area ( BSA ) great equal 10 % Must meet specific laboratory criterion Must candidate photo/systemic therapy Women childbearing potential must negative pregnancy test Must clinically significant underlying disease process Must pregnant lactating female Must condition , include lab abnormality , place subject unacceptable risk subject participate study confound ability interpret data study Must history active mycobacterium tuberculosis infection within 3 year prior screen visit Must history incompletely treat active latent mycobacterium tuberculosis infection Must know history exposure infectious case mycobacterium tuberculosis within 2 year prior screen visit Must immigrant form highincidence country mycobacterium tuberculosis disease within 2 year prior screen visit Must current erythrodermic , guttate , pustular psoriasis Must clinical history failure adequately respond treatment investigator 's opinion one treatment course cyclosporine follow biologic therapy : alefacept , etanercept , efalizumab , infliximab adalimumab Must use topical therapy within 14 day randomization Must use systemic therapy psoriasis within 28 day randomization Must use phototherapy within 28 day randomization Must use adalimumab infliximab within 3 month randomization Must use etanercept efalizumab within 56 day randomization Must use alefacept within 6 month randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>plaque psoriasis</keyword>
</DOC>